Moderna MRNA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Contract with Customer, Liability by Product | ||||||
| Net product sales | $95M-11.2% | $107M-25.7% | $144M-34.8% | $221M+43.5% | $154M-18.1% | |
| Other revenue | $161M+11.0% | $145M-17.6% | $176M+184% | $62M+114% | $29M+26.1% | |
| Total Revenue by Product | ||||||
| Collaboration Arrangement, Including Arrangements With Affiliate | $5M+400% | $1M-85.7% | $7M+75.0% | $4M+300% | $1M-92.3% | |
| Grant revenue | $0-100% | $2M-85.7% | $14M+180% | $5M+400% | $1M-90.0% | |
| Licensing and royalty revenue | $0— | $0-100% | $2M0.0% | $2M-75.0% | $8M+60.0% | |
| Stand-ready manufacturing revenue | $32M— | —— | —— | —— | $12M— | |
| Additions by Product | ||||||
| Net product sales | $0-100% | $24M— | $0-100% | $84M— | $0-100% | |
| Other revenue | $53M+2,550% | $2M-98.6% | $146M+192% | $50M+257% | $14M— | |
| Contract With Customer, Liability, Deductions During Period by Product | ||||||
| Net product sales | $12M-80.3% | $61M-20.8% | $77M+353% | $17M-50.0% | $34M-86.7% | |
| Other revenue | $37M+12.1% | $33M+3.1% | $32M+88.2% | $17M+113% | $8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Moderna break its business down?
- Moderna (MRNA) reports contract with customer, liability by product across 2 parts — Net product sales and Other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Moderna's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Moderna's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
